
Gilead Sciences GILD
$ 138.79
-0.96%
Annual report 2025
added 02-24-2026
Gilead Sciences Depreciation & Amortization 2011-2026 | GILD
Annual Depreciation & Amortization Gilead Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 370 M | 381 M | 354 M | 323 M | 329 M | 288 M | 255 M | 226 M | 233 M | 177 M | 161 M | 125 M | 103 M | 83 M | 72.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 381 M | 72.2 M | 232 M |
Quarterly Depreciation & Amortization Gilead Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 90 M | 93 M | 97 M | - | 94 M | 98 M | 94 M | - | 598 M | 598 M | 94 M | - | 445 M | 445 M | 80 M | - | 239 M | 157 M | 78 M | - | 209 M | 136 M | 68 M | - | 186 M | 120 M | 60 M | - | 169 M | 112 M | 56 M | - | 155 M | 103 M | 49 M | - | 129 M | 85 M | 42 M | - | 116 M | 75 M | 37 M | - | 94 M | 53 M | 24 M | - | 76 M | 50.1 M | 24 M | - | 60.5 M | 39.9 M | 19.7 M | - | 53.2 M | 36 M | 18.3 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 598 M | 18.3 M | 128 M |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.38 | -1.08 % | $ 367 M | ||
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | ||
|
DBV Technologies S.A.
DBVT
|
2.99 M | $ 20.52 | 0.79 % | $ 2.86 B | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | ||
|
Aytu BioScience
AYTU
|
5.38 M | $ 2.57 | -3.48 % | $ 16.1 M | ||
|
Forte Biosciences
FBRX
|
64 K | $ 26.92 | 1.8 % | $ 349 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
Fulcrum Therapeutics
FULC
|
1.39 M | $ 7.72 | -1.4 % | $ 489 K | ||
|
Galectin Therapeutics
GALT
|
1 K | $ 2.24 | -12.55 % | $ 143 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
42 K | $ 0.56 | 8.45 % | $ 521 K | ||
|
Gossamer Bio
GOSS
|
24 K | $ 0.32 | -7.03 % | $ 73.1 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
GT Biopharma
GTBP
|
4 K | $ 0.41 | -7.26 % | $ 2.26 M | ||
|
Halozyme Therapeutics
HALO
|
11.4 M | $ 63.49 | 0.64 % | $ 7.61 B | ||
|
Coherus BioSciences
CHRS
|
1.3 M | $ 1.62 | -3.1 % | $ 190 M | ||
|
Akari Therapeutics, Plc
AKTX
|
14 K | $ 3.32 | -6.21 % | $ 224 B | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M | ||
|
Allena Pharmaceuticals
ALNA
|
363 K | - | 3.16 % | $ 1.9 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
55.7 M | $ 318.56 | -3.57 % | $ 41.7 B | ||
|
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B | ||
|
Harmony Biosciences Holdings
HRMY
|
23.8 M | $ 27.62 | -0.34 % | $ 1.59 B | ||
|
Aileron Therapeutics
ALRN
|
1 K | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
iBio
IBIO
|
484 K | $ 2.08 | 2.47 % | $ 21.8 M | ||
|
ImmuCell Corporation
ICCC
|
2.78 M | $ 6.54 | -1.06 % | $ 59 M |